TD Cowen analyst Charles Rhyee maintained a Buy rating on McKesson (MCK – Research Report) today and set a price target of $695.00. The company’s shares closed yesterday at $643.69.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
According to TipRanks, Rhyee is a 2-star analyst with an average return of 0.0% and a 45.12% success rate. Rhyee covers the Healthcare sector, focusing on stocks such as Walgreens Boots Alliance, CVS Health, and IQVIA Holdings.
McKesson has an analyst consensus of Strong Buy, with a price target consensus of $672.50, implying a 4.48% upside from current levels. In a report released on February 18, Robert W. Baird also maintained a Buy rating on the stock with a $730.00 price target.
MCK market cap is currently $80.67B and has a P/E ratio of 29.50.
Read More on MCK:
- McKesson CEO Tyler sells $5.36M of shares
- McKesson designated a Bullish Fresh Pick at Baird
- McKesson’s Earnings Call Highlights Strong Growth
- McKesson, AmerisourceBergen succeed in dismissing claims, Bloomberg Law says
- Optimistic Growth Prospects: Charles Rhyee’s Buy Rating on McKesson Despite Medical Segment Shortfall